Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,069 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Recruiting Phase 1Phase 2 Interventional

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

NCT05490472
View directory record Official record
Conditions
Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC
Interventions
JAB-2485 (Aurora A inhibitor)
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Detroit, Michigan • St Louis, Missouri • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 19, 2026, 10:05 PM EDT
Recruiting Early Phase 1 Interventional

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

NCT06008275
View directory record Official record
Conditions
Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
Interventions
Neratinib Oral Tablet, Ruxolitinib Oral Tablet
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 10:05 PM EDT
Recruiting Phase 1 Interventional

IDOV-Immune for Advanced Solid Tumors

NCT06910657
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions
IDOV-Immune (oncolytic vaccinia virus)
Biological
Lead sponsor
ViroMissile, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 19, 2026, 10:05 PM EDT
Not listed Phase 3 Interventional

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

NCT01204801
View directory record Official record
Conditions
Breast Cancer
Interventions
Focused Microwave Thermotherapy, Chemotherapy (control)
Device · Drug
Lead sponsor
Medifocus, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 19, 2026, 10:05 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

NCT00343512
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, protein expression analysis, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 19, 2026, 10:05 PM EDT
Suspended Phase 1 Interventional

Pilot Trial of Preop Partial Radiation in Breast Cancer Patients

NCT07178665
View directory record Official record
Conditions
Early-stage Breast Cancer, Breast Carcinoma, DCIS
Interventions
Radiation: Accelerated Partial Breast Irradiation (APBI)
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 19, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy

NCT03430765
View directory record Official record
Conditions
Persistent Postsurgical Pain, Breast Cancer Female, Ductal Carcinoma in Situ
Interventions
Acceptance and Commitment Therapy
Behavioral
Lead sponsor
Katherine Hadlandsmyth
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Oct 19, 2026, 10:05 PM EDT
Completed No phase listed Observational

Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation Oncology

NCT02756767
View directory record Official record
Conditions
Patients With Lung, Breast, Head and Neck, or Pelvic Malignancies
Interventions
Survey
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 19, 2026, 10:05 PM EDT
Completed Not applicable Interventional

VR Ultrasound Guided Breast Localization

NCT04251507
View directory record Official record
Conditions
Breast Neoplasm Female
Interventions
Oculus Go Virtual Reality Goggles
Device
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 19, 2026, 10:05 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration

NCT00896636
View directory record Official record
Conditions
Breast Cancer, Healthy, no Evidence of Disease
Interventions
Random fine need aspiration (rFNA), Mammogram
Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 19, 2026, 10:05 PM EDT
Terminated No phase listed Observational

Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

NCT05236387
View directory record Official record
Conditions
Breast Cancer
Interventions
99m Tc-TM
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 19, 2026, 10:05 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
Interventions
IDE-161, Pembrolizumab
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 19, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants

NCT04252300
View directory record Official record
Conditions
Drug Interactions
Interventions
Rosuvastatin, Rosuvastatin + BAY1817080
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 19, 2026, 10:05 PM EDT
Completed Phase 1Phase 2 Interventional

LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

NCT04261387
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
LUT014 Gel, Placebo for LUT014 Gel
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Columbus, Georgia • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 19, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Exercise Program in Cancer and Cognition

NCT02793921
View directory record Official record
Conditions
Breast Cancer
Interventions
Moderate-Intensity Aerobic Exercise Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 19, 2026, 10:05 PM EDT
Completed No phase listed Observational

The Impact of Lymphedema on Breast Cancer Survivors

NCT00769821
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Lymphedema, Perioperative/Postoperative Complications
Interventions
questionnaire administration, assessment of therapy complications, bioimpedance spectroscopy, quality-of-life assessment
Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older · Female only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Oct 19, 2026, 10:05 PM EDT
Recruiting Phase 3 Interventional

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

NCT06763328
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions
Biospecimen Collection, Educational Intervention, Extended Release Metformin Hydrochloride, Questionnaire Administration
Procedure · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Duarte, California • La Jolla, California • Riverside, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

Irinotecan and Capecitabine in Treating Patients With Solid Tumors

NCT00003867
View directory record Official record
Conditions
Cancer
Interventions
capecitabine, irinotecan hydrochloride
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 19, 2026, 10:05 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Testing Conversation Aid in Practice

NCT06011434
View directory record Official record
Conditions
Breast Cancer
Interventions
Mammography Screening Conversation Aid
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
75 Years to 89 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 19, 2026, 10:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

NCT00063934
View directory record Official record
Conditions
Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
oblimersen sodium, doxorubicin hydrochloride, docetaxel, filgrastim, pegfilgrastim, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 19, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

NCT02073487
View directory record Official record
Conditions
Breast Cancer
Interventions
T-DM1, Trastuzumab, Lapatinib, Abraxane, Paclitaxel, Pertuzumab
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 19, 2026, 10:05 PM EDT
Terminated Early Phase 1 Interventional

Breast-Sparing Proton Therapy for Hodgkin's Disease

NCT02070393
View directory record Official record
Conditions
Hodgkins Disease
Interventions
Proton
Radiation
Lead sponsor
Indiana University
Other
Eligibility
10 Years to 30 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Oct 19, 2026, 10:05 PM EDT
Completed No phase listed Observational

Morphine for the Treatment of Pain in Patients With Breast Cancer

NCT00003000
View directory record Official record
Conditions
Pain
Interventions
fentanyl citrate, morphine sulfate
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 19, 2026, 10:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Endocrine Therapy (ET)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 10:05 PM EDT